Insulin resistance in chronic heart failure: A difficult bull to take by the horns

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 5, 2009, Pages 303-305

  Sacca L ^a   Napoli, R ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

CHRONIC DISEASE; EDITORIAL; GLUCOSE BLOOD LEVEL; HEART FAILURE; HUMAN; INSULIN RESISTANCE; METABOLISM;

BLOOD GLUCOSE; CHRONIC DISEASE; HEART FAILURE; HUMANS; INSULIN; INSULIN RESISTANCE;

EID: 67349119824     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2008.09.002     Document Type: Editorial

References (31)

1. Witteles R.M., Wilson Tang W.H., Jamali A.H., Chu J.W., Reaven J.M., and Fowler M.B. Insulin resistance in idiopathic dilated cardiomyopathy. J Am Coll Cardiol 44 (2004) 78-81
2. Swan J.W., Anker S.D., Walton C., Godsland I.F., Clark A.L., Leyva F., et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. J Am Coll Cardiol 30 (1997) 527-532
3. Suskin N., McKelvie R.S., Burns R.J., Latini R., Pericak D., Probstfield J., et al. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure. Eur Heart J 21 (2000) 1368-1375
4. Greenberg B.H., Abraham W.T., Albert N.M., Chiswell K., Clare R., Stough W.G., et al. Influence of diabetes on characteristics and outcomes in patients hospitalized with heart failure: a report from the organized program to initiate lifesaving treatment in hospitalized HF patients. Am Heart J 154 (2007) 647-654
5. Nikolaidis L.A., Sturzu A., Stolarski C., Elahi D., Shen Y.T., and Shannon R.P. The development of myocardial insulin resistance in conscious dogs with advanced dilated cardiomyopathy. Cardiovasc Res 61 (2004) 297-306
6. Taylor M., Wallhaus T.R., Degrado T.R., Russell D.C., Stanko P., Nickles R.J., et al. An evaluation of myocardial fatty acid and glucose uptake using PET with [18F]fluoro-6-thia-heptadecanoic acid and [18F]FDG in patients with congestive heart failure. J Nucl Med 42 (2001) 55-62
7. Dutka D.P., Pitt M., Pagano D., Mongillo M., Gathercole D., Bonser R.S., et al. Myocardial glucose transport and utilization in patients with type 2 diabetes mellitus, left ventricular dysfunction, and coronary artery disease. J Am Coll Cardiol 48 (2006) 2225-2231
8. Ingwall J.S., and Weiss R.G. Is the failing heart energy starved? On using chemical energy to support cardiac function. Circ Res 95 (2004) 135-145
9. Neubauer S. The failing heart: an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
10. Ashrafian H., Frenneaux M.P., and Opie L.H. Metabolic mechanisms in heart failure. Circulation 116 (2007) 434-448
11. Avogaro A., Nosadini R., Doria A., Fioretto P., Velussi M., Vigorito C., et al. Myocardial metabolism in insulin-deficient diabetic humans without coronary artery disease. Am J Physiol 258 (1990) E606-E608
12. Doehner W., Rauchhaus M., Ponikowski P., Godsland I.F., von Haehling S., Okonko D.O., et al. Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure. J Am Coll Cardiol 46 (2005) 1019-1026
13. Kahn C.R., Chen L., and Cohen S.E. Unraveling the mechanism of action of thiazolidinediones. J Clin Invest 106 (2000) 1305-1307
14. Qayyum R., and Schulman P. Cardiovascular effects of the thiazolidinediones. Diabetes Metab Res Rev 22 (2006) 88-97
15. Lautamäki R., Airaksinen K.E., Seppänen M., Toikka J., Luotolahti M., Ball E., et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Diabetes 54 (2005) 2787-2794
16. Nemoto S., Razeghi P., Ishiyama M., De Freitas G., Taegtmeyer H., and Carabello B.A. PPAR-gamma agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 288 (2005) H77-H82
17. Dargie H.J., Hildebrandt P.R., Riegger G.A., McMurray J.J., McMorn S.O., Roberts J.N., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York heart association functional class I or II heart failure. J Am Coll Cardiol 49 (2007) 1696-1704
18. Sambanis C., Tziomalos K., Kountana E., Kakavas N., Zografou I., Balaska A., et al. Effect of pioglitazone on heart function and N-terminal pro-brain natriuretic peptide levels of patients with type 2 diabetes. Acta Diabetol 45 (2008) 23-30
19. Horio T., Suzuki M., Suzuki K., Takamisawa I., Hiuge A., Kamide K., et al. Pioglitazone improves left ventricular diastolic function in patients with essential hypertension. Am J Hypertens 18 (2005) 949-957
20. Shiomi T., Tsutsui H., Hayashidani S., Suematsu N., Ikeuchi M., Wen J., et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106 (2002) 3126-3132
21. Lago R.M., Singh P.P., and Nesto R.W. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 370 (2007) 1129-1136
22. Lincoff A.M., Wolski K., Nicholls S.J., and Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 298 (2007) 1180-1188
23. Singh S., Loke Y.K., and Furberg C.D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA 298 (2007) 1189-1195
24. Hardie D.G. Role of AMP-activated protein kinase in the metabolic syndrome and in heart disease. FEBS Lett 582 (2008) 81-89
25. Saeedi R., Parsons H.L., Wambolt R.B., Paulson K., Sharma V., Dyck J.R., et al. Metabolic actions of metformin in the heart can occur by AMPK-independent mechanisms. Am J Physiol Heart Circ Physiol 294 (2008) H2497-H2506
26. Bertrand L., Ginion A., Beauloye C., Hebert A.D., Guigas B., Hue L., et al. AMPK activation restores the stimulation of glucose uptake in an in vitro model of insulin-resistant cardiomyocytes via the activation of protein kinase B. Am J Physiol Heart Circ Physiol 291 (2006) H239-H250
27. Masoudi F.A., Inzucchi S.E., Wang Y., Havranek E.P., Foody J.M., and Krumholz H.M. Thiazolidinediones, metformin, and outcomes in older patients with diabetes and heart failure: an observational study. Circulation 111 (2005) 583-590
28. Eurich D.T., Majumdar S.R., McAlister F.A., Tsuyuki R.T., and Johnson J.A. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care 28 (2005) 2345-2351
29. Zhao T., Parikh P., Bhashyam S., Bolukoglu H., Poornima I., Shen Y.T., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 317 (2006) 1106-1113
30. Nikolaidis L.A., Elahi D., Hentosz T., Doverspike A., Huerbin R., Zourelias L., et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 110 (2004) 955-961
31. Sokos G.G., Nikolaidis L.A., Mankad S., Elahi D., and Shannon R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail 12 (2006) 694-699